RxDoctor Payments Data

Sandra Pike, NP

Family · Oswego, NYNPI 1255598868

Payments from drug & device makers

$1,124in general payments, 2019–2025

Across 66 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$321
  • AbbVie$171
  • Novo Nordisk$168
  • AstraZeneca$167
  • Exact Sciences$54
  • Abbott$52
  • plus $190 from 9 others

What the payments were for

  • Food & beverage$1,124100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,124 in reported general payments places this provider in the 75th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$22,269
Medicare patients
164
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$76,875
EliquisApixaban70$72,401
JanuviaSitagliptin Phosphate31$45,751
FarxigaDapagliflozin Propanediol30$37,268
MounjaroTirzepatide34$35,963
XareltoRivaroxaban26$30,710
OzempicSemaglutide14$23,191
JardianceEmpagliflozin25$19,747
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$18,559
OxycontinOxycodone Hcl24$18,383
MyrbetriqMirabegron20$16,411
VascepaIcosapent Ethyl32$14,771
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$14,593
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$12,782
Breo ElliptaFluticasone/Vilanterol22$11,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Shingrix$321$105,750151 claims
PfizerEliquis, Abrysvo$17$77,70888 claims
AstraZenecaFarxiga, Breztri Aerosphere$167$51,86141 claims
MerckJanuvia$15$45,75131 claims
Lilly USA, LLCMounjaro$14$35,96334 claims
Novo NordiskOzempic$168$23,19114 claims
Boehringer IngelheimJardiance$26$19,74725 claims
AbbVieSynthroid$171$2,79928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,883 family providers in New York.

Other family in Oswego

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →